Barriers and Breakthroughs in Precision Oncology: A National Registry Study of <i>BRCA</i> Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR).

Cancers (Basel) · 2025 · PMC12346830 · PMID 40805236

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp < 0.001actually significant

A more pronounced and highly significant increase was seen in somatic testing, which rose from 23.7% (193/814) to 44.2% (234/529) ( p < 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Barriers and Breakthroughs in Precision Oncology: A National Registry Study of &lt;i&gt;BRCA&lt;/i&gt; Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR).

The sentences

Barriers and Breakthroughs in Precision Oncology: A National Registry Study of <i>BRCA</i> Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR).